Minerva Neurosciences reported $3.25M in Current Liabilities for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US $ 119.6M 23.54M
Adma Biologics ADMA:US $ 31.57M 1.19M
ALKERMES ALKS:US $ 462.36M 8.93M
AstraZeneca AZN:LN 22740M 146M
Biocryst Pharmaceuticals BCRX:US $ 81.02M 22.7M
Bristol Myers Squibb BMY:US $ 22821M 953M
Dynavax Technologies DVAX:US $ 466.2M 90.2M
Eli Lilly And LLY:US $ 13386M 1666.7M
Esperion Therapeutics ESPR:US $ 79.08M 5.73M
GlaxoSmithKline GSK:LN 24278M 608M
Halozyme Therapeutics HALO:US $ 111.69M 5.46M
Johnson & Johnson JNJ:US $ 43390M 1836M
Marinus Pharmaceuticals MRNS:US $ 19.54M 21.03M
Merk MRK:US $ 22316M 1556M
Minerva Neurosciences NERV:US $ 3.25M 0.43M
Neurocrine Biosciences NBIX:US $ 253.5M 7.7M
Novartis NOVN:VX SF 29807M 401M
Novavax NVAX:US $ 2261M 129.31M
Pfizer PFE:US $ 39268M 3403M
Takeda 4502:JP Y 2145730M 336476M
Vanda Pharmaceuticals VNDA:US $ 90.74M 16.32M